Predict your next investment

Bormioli Pharma company logo
Corporation
BUSINESS PRODUCTS & SERVICES | Packaging
bormiolipharma.com

See what CB Insights has to offer

Partners & Customers

1

About Bormioli Pharma

Bormioli Pharma specializes in healthcare packaging solutions and is based in Italy.

Bormioli Pharma Headquarter Location

Corso Magenta, 84

Milan, 20123,

Italy

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Bormioli Pharma News

From bioplastics to bioproducts

Sep 17, 2021

From bioplastics to bioproducts × Shutterstock According to European Bioplastics, the association representing the industry in Europe, bioplastics are not just one single material, but comprise a whole family of materials with different properties and applications that comply with one of the following three features:  biobased , biodegradable or both. The term ‘biobased’ means that the material or product is derived — at least partially — from biomass, such as corn, starch, sugar cane, cellulose or other raw materials that are not included in the human or breeding food chain. Biodegradable means that the material can perform a chemical process during which microorganisms convert materials into natural substances, without the need for any artificial additives. Biobased and biodegradable are not, therefore, synonyms, as the biodegradation process does not depend on the resource basis of a material, but rather is linked to its chemical structure. Bioplastics represent an answer for the industry to develop a more circular economy , that — according to the Ellen MacArthur Foundation — is “restorative and regenerative by design, aiming to keep products, components and materials at their highest utility and value at all times, distinguishing between technical and biological cycles”. With this definition in mind, bioplastics fit into this new economic concept as they help to break away from the linear economy characterised by ‘make, use, dispose of’ in favour of a more circular model based on ‘make, use, reuse, recycle’, contributing to closing the loop in regenerating CO2 and using renewable raw materials to make everyday products more sustainable. Beyond bioplastics Bormioli Pharma, for example, goes beyond the simple concept of bioplastic, which better suits raw material producers, to ‘bioproduct’, a wider philosophy that it applies to all of its production. This approach provides a new way to create and develop products and value, committing to production and development choices that bring life cycle assessment (LCA) benefits. This tailor-made product development is conducted step-by-step together with the client, supporting and advising them on the most suitable choices that can be applied based on their specific needs and requirements. This circular innovation approach is the result of 10-years’ experience in the research of alternative plastic packaging solutions. During this time, the company has been investigating a range of sustainable products, starting with mechanical recycled polyethylene terephthalate (rPET) bottle solutions, which are already used and commercialised within the pharmaceutical and nutraceutical markets. Over the years, the company has looked for new, sustainable innovations, starting from chemical rPET for pharma use, up to the latest breakthrough that the company intends to introduce to its pharma partners later this year: PET containers partially manufactured from monoethylene glycol, (MEG) via the recovery of CO2 emissions and subsequent gasification and fermentation processes. The company’s commitment to guaranteeing ever-lower greenhouse gas (GHG) emissions is based on some fundamental pillars. First, it focuses on European producers to ensure the strictest environmental commitments and to cut GHG emissions derived from logistics; then, its products are specifically engineered to make recycling at the end of the lifecycle easier. Finally, the company constantly support clients with specific tests to combine a circular economy with the strictest safety criteria that the pharmaceutical market requires, making the packaging validation phase simpler. Products As regards specific bioproducts, Bormioli Pharma’s range of containers and accessories are manufactured from different polymers such as polylactic acid (PLA), Green PE, Green PP and BioPET. Biobased solutions are particularly present in Bormioli Pharma’s forLife portfolio — a range of packaging products for nutraceuticals and food supplements. Growing interest is also being seen in the oral drugs market, with the development of pillboxes manufactured from biobased plastics. The company’s dosing solutions (for example, spoons and scoops) made with eco-friendly materials need to follow the usual approval process. PLA solutions are preferred for pharma packaging accessories such as cups and spoons. Fully degradable within 60 days in industrial compost facilities, these solutions feature a food-grade certification for the EU and the US, as well as excellent physical/mechanical properties. Although recycling regulations vary from country to country, the company aims to contribute to the creation of a ‘seventh recycling chain’ specifically created for compostable plastics that could further facilitate the disposal of these products. Other concepts manufactured by Bormioli Pharma using bioplastics that have been introduced to players in the pharmaceutical industry are Green PE bottles, Green PE-PP caps and containers and BioPET bottles. The former (Green PE bottles and Green PP caps) are manufactured from up to 100% biobased plastic, and their adoption has no impacts on the packaging lines. The latter are produced from the polymerisation of renewable materials and are entirely recyclable. All of these solutions are compliant with food contact pharma regulations both in the EU and the US. Open innovation Bormioli Pharma’s open innovation approach to continuous development of advanced solutions has already guaranteed outstanding results in research fields such as product usability and IoT (internet of Things) integration, through the creation of an open environment and multiplying the company’s R&D efforts thanks to the contributions of external players, such as end users, clients and partners, but also start-ups, research centres, universities, innovation hubs and accelerators. This ecosystem allows the company to understand clients’ needs and new challenges and opportunities. Roberto Valenti, head of materials development at Bormioli Pharma The topics of circular economy and innovation are increasingly being addressed; they’re even constituting the focus of strategic, international policies, such as the European Green Deal and Recovery Plan. Bormioli Pharma contributes to promoting sustainability within the pharmaceutical industry as it combines the principle of a circular economy with the strict normative framework required by this specific sector, thus favouring a widespread adoption of biopackaging by markets and patients.

Bormioli Pharma Acquisitions

5 Acquisitions

Bormioli Pharma acquired 5 companies. Their latest acquisition was Cricef Contagocce on June 10, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

6/10/2021

Acquired

1

12/1/2020

Subscribe to see more

$99M

Subscribe to see more

10

4/16/2020

Subscribe to see more

$99M

Subscribe to see more

10

10/8/2019

Subscribe to see more

$99M

Subscribe to see more

10

9/23/2019

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/10/2021

12/1/2020

4/16/2020

10/8/2019

9/23/2019

Investment Stage

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

Total Funding

$99M

$99M

$99M

$99M

Note

Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Bormioli Pharma Partners & Customers

1 Partners and customers

Bormioli Pharma has 1 strategic partners and customers. Bormioli Pharma recently partnered with Stevanato Group on February 2, 2020.

Date

Type

Business Partner

Country

News Snippet

Sources

2/4/2020

Partner

Stevanato Group

Italy

Stevanato Group and Bormioli Pharma sign a collaboration agreement for glass molded vials in EZ-fill® configuration - StevanatoGroup

Stevanato Group , through Ompi , its specialist in glass primary packaging for the pharmaceutical industry , and Bormioli Pharma announce today a collaboration agreement .

1

Date

2/4/2020

Type

Partner

Business Partner

Stevanato Group

Country

Italy

News Snippet

Stevanato Group and Bormioli Pharma sign a collaboration agreement for glass molded vials in EZ-fill® configuration - StevanatoGroup

Stevanato Group , through Ompi , its specialist in glass primary packaging for the pharmaceutical industry , and Bormioli Pharma announce today a collaboration agreement .

Sources

1

Bormioli Pharma Team

2 Team Members

Bormioli Pharma has 2 team members, including current Chief Executive Officer, Andrea Lodetti.

Name

Work History

Title

Status

Andrea Lodetti

Chief Executive Officer

Current

Alberto Romagnoli

Chief Financial Officer

Current

Name

Andrea Lodetti

Alberto Romagnoli

Work History

Title

Chief Executive Officer

Chief Financial Officer

Status

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.